Bengaluru-based LiteFold launched an AI platform called Rosalind to unblock computational biologists in drug discovery. Founder Anindyadeep Sannigrahi noticed these biologists spend significant time building their own software tools before even starting research. LiteFold claims its "AI co-scientist" can run hundreds of drug hypotheses in parallel, dramatically speeding up the early stages of therapeutic development.
How We Got Here
Sannigrahi began work on protein folding in 2025, just a year after the Nobel Prize recognized breakthroughs in computational protein design. He built the initial tech at Lossfunk's AI residency, connecting with co-founder Cory Kornowicz via X before officially launching LiteFold in 2025.
The Numbers
- LiteFold is a five-member startup operating out of Bengaluru and Delaware in the US.
- The platform, Rosalind, aims to streamline multiple stages from AI workflows to legal processes, excluding wet lab testing.
- Co-founder Cory Kornowicz is an American computational biologist and ML engineer.
- The company intends to grow from therapeutic design into broader biological engineering.
What Happens Next
🇮🇳 Why This Matters for India
For the emerging biotech startups and computational biologists in Hyderabad and Pune, LiteFold offers a direct pathway to accelerate drug discovery without building proprietary tools from scratch.
The Take
LiteFold correctly identified that the real bottleneck in computational biology is the lack of robust, integrated software tooling. This "IDE for computational biologists" approach will likely see faster adoption than pure discovery platforms, particularly within cash-strapped early-stage biotech labs.
Source:
YourStory ↗